Table 1.
Baseline characteristics and descriptive analysis of ponatinib usage
| CP (n = 51) | AP (n = 9) | BP (n = 18) | |
|---|---|---|---|
| Patients, n | 51 | 9 | 18 |
| Sex, male/female, n | 27/24 | 3/6 | 10/8 |
| Median age (range), y | 42 (17-70) | 38 (14-54) | 46.5 (20-69) |
| Vascular risk factors before ponatinib, n (%) | |||
| HTN | 9 (17.6) | 1 (11.1) | 6 (33.3) |
| CVA | 0 (0) | 0 (0) | 0 (0) |
| DM | 0 (0) | 1 (11.1) | 3 (16.7) |
| PAD | 1 (2.0) | 1 (11.1) | 0 (0) |
| MI | 5 (9.8) | 1 (11.1) | 1 (5.5) |
| Lines of therapy, n | |||
| Second | 4 | 1 | 0 |
| Third | 17 | 2 | 7 |
| Fourth | 16 | 5 | 6 |
| Fifth | 6 | 0 | 3 |
| ≥Sixth | 8 | 1 | 2 |
| Mean ponatinib starting dose, mg/d | 39.65 | 41.95 | 38.59 |
| Had dose reduction, n (%) | 33 (64.7) | 7 (77.8) | 8 (44.4) |
| Median ponatinib duration, mo | 14.60 | 10.47 | 5.02 |
| Reason for ponatinib, n (%) | |||
| T315I mutation | 12 (23.5) | 1 (11.1) | 3 (16.7) |
| Failure without T315I | 39 (76.5) | 8 (88.9) | 15 (83.3) |
AP, accelerated phase; BP, blast phase; CVA, cerebrovascular accident; DM, diabetes; HTN: hypertension; PAD, peripheral arterial disease.